The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., GE Aerospace and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Lilly is also developing oral therapies for its gastroenterology pipeline.

Eli Lilly’s Alzheimer’s treatment, Kisunla (donanemab), scored a major win with approval in Australia, marking it as the ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

1 The Company defines Key Products as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound. First-Quarter Non-GAAP Measures On a non-GAAP basis, Q1 2025 gross margin increased 47% ...

(Annals of Internal Medicine) A small case series published in Inflammatory Bowel Diseases showed that patients with moderately active ulcerative colitis can benefit from mirikizumab (Omvoh ...

along with approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY), one of the best dividend zombies, has been paying dividends to ...

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...

Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...